Processing

Please wait...

Settings

Settings

Goto Application

1. WO2021010712 - ANTI-TAU ANTIBODY AND USE OF SAME

Publication Number WO/2021/010712
Publication Date 21.01.2021
International Application No. PCT/KR2020/009207
International Filing Date 13.07.2020
IPC
C07K 16/18 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
A61P 25/28 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
28for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
G01N 33/68 2006.01
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
68involving proteins, peptides or amino acids
A61K 39/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
Applicants
  • 주식회사 아델 ADEL, INC. [KR]/[KR]
Inventors
  • 윤승용 YOON, Seung-Yong
Agents
  • 제일특허법인(유) FIRSTLAW P.C.
Priority Data
10-2019-008523315.07.2019KR
Publication Language Korean (KO)
Filing Language Korean (KO)
Designated States
Title
(EN) ANTI-TAU ANTIBODY AND USE OF SAME
(FR) ANTICORPS ANTI-TAU ET SON UTILISATION
(KO) 항-타우 항체 및 이의 용도
Abstract
(EN)
The present invention relates to an anti-tau antibody specifically binding to a tau protein, and a use of same. The anti-tau antibody according to the present invention specifically binds to a tau protein in which lysine at position 280 is acetylated and can suppress abnormal aggregation of tau proteins. In addition, the anti-tau antibody according to the present invention, when administered to an animal model of induced dementia, can improve locomotor activity and cognitive ability in the animal model. Therefore, the anti-tau antibody according to the present invention may be utilized in the prevention or treatment of neurodegenerative diseases.
(FR)
La présente invention concerne un anticorps anti-tau se liant spécifiquement à une protéine tau, et son utilisation. L'anticorps anti-tau selon la présente invention se lie spécifiquement à une protéine tau dans laquelle la lysine en position 280 est acétylée, et peut supprimer l'agrégation anormale de protéines tau. De plus, l'anticorps anti-tau selon la présente invention, lorsqu'il est administré à un modèle animal souffrant de démence induite, peut améliorer l'activité locomotrice et la capacité cognitive chez le modèle animal. Par conséquent, l'anticorps anti-tau de la présente invention peut être utilisé dans la prévention ou le traitement de maladies neurodégénératives.
(KO)
본 발명은 타우 단백질에 특이적으로 결합하는 항-타우 항체 및 이의 용도에 관한 것이다. 본 발명에 따른 항-타우 항체는 280번째 라이신이 아세틸화된 타우 단백질에 특이적으로 결합하며, 비정상적인 타우 단백질의 응집을 억제시킬 수 있다. 또한, 본 발명에 따른 항-타우 항체를 치매 유발 동물모델에 투여할 경우, 상기 동물모델의 운동능력 및 인지능력을 개선시킬 수 있다. 따라서, 본 발명에 따른 항-타우 항체는 퇴행성 신경 질환의 예방 또는 치료에 유용하게 사용될 수 있다.
Also published as
Latest bibliographic data on file with the International Bureau